The effect of natalizumab on disability score and relapse rate of multiple sclerosis patients: a prospective cohort study

Clinical and Translational Medicine

Table 3 EDSS scores in the study group in each time intervals

Time intervals	Paired difference			t	df	Sig (2-tailed)
Time intervals	Mean	Standard deviation	95% confidence interval	t	df	Sig (2-tailed)
1–12	1.48	1.36	0.84, 2.11	4.84	19	< 0.001
2–12	1.48	1.34	0.85, 2.10	4.91	19	< 0.001
3–12	1.48	1.15	0.94, 2.01	5.72	19	< 0.001
4–12	1.28	1.04	0.79, 2.76	5.46	19	0.001
5–12	1.13	1.02	0.65, 2.60	4.91	19	0.016
6–12	0.98	0.98	0.52, 1.43	4.45	19	0.016
7–12	0.88	0.90	0.45, 1.30	4.34	19	0.006
8–12	0.65	0.71	0.32, 0.98	4.10	19	0.088
9–12	0.58	0.71	0.24, 0.91	3.61	19	0.601
10–12	0.35	0.59	0.08, 0.62	3.67	19	0.083
11–12	0.15	0.33	0.00, 0.30	2.04	19	0.032